Request paper copies of the meeting materials online, by email or by phone by dialing 866-648-8133.
Your vote is important!
Please be sure to vote online now or by phone by dialing
866-829-5219.
Thursday, June 4, 2026
8:30 AM Pacific Time
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at www.kuraoncology.com and follow us on X and Linkedin.